| Previous 10 | Next 10 |
BPMC News and Press Blueprint Medicines Corporation From...
-
Blueprint Medicines press release ( NASDAQ: BPMC ): Q3 GAAP EPS of -$2.23 beats by $0.28 . Revenue of $65.97M (+172.7% Y/Y) beats by $22.09M . GUIDANCE: Blueprint Medicines anticipates it will achieve the high end of previously provided revenue guidance for ful...
-
Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and Reports Third Quarter 2022 Financial Results at Investor Day 2022 PR Newswire -- On track to submit supplemental new drug application for AYVAKIT® (avapritinib) in non-advanced ...
-
Blueprint Medicines to Host Investor Day and Announce Third Quarter 2022 Financial Results on November 1, 2022 PR Newswire CAMBRIDGE, Mass. , Oct. 19, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused...
-
Summary Shares have fallen by around 80% over the past year. EGFR/HER2 exon 20 and PRC2 inhibitors offer potentially differentiated shots on goal with early data sets expected 1H 2023. Depth and experience of leadership team is a green flag (ex-Ignyta, Medivation, Genentech). ...
-
Summary Blueprint has a few recently approved therapies, and has recently sold royalties for over $1 billion. While this limits revenue potential now, the profits can be leveraged back into advancing the pipeline. Blueprint can now be assessed like a pre-commercial biotech wit...
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass. , Sept. 6, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined ca...
-
CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis PR Newswire -- Patients across the spectrum of disease reported substantial symptom burden, as well as scores of physical functioning and mental health that are wors...
-
Gainers: Blue Water Vaccines ( BWV ) +57% . Eargo ( EAR ) +49% . Cassava Sciences ( SAVA ) +29% . MiNK Therapeutics ( INKT ) +24% . Cogent Biosciences ( COGT ) +16% . Losers: Blueprint Medicines ( BPMC ) -22% ....
-
Blueprint Medicines ( BPMC ) -13% on reports to seek label expansion for systemic mastocytosis therapy after trial win . Artelo Biosciences ( ARTL ) -13% . Krispy Kreme ( DNUT ) -12% on Q2 earnings release . Forza X1 ( FRZA ) -12% . ...
-
Blueprint Medicines ( NASDAQ: BPMC ), the maker of systemic mastocytosis therapy Ayvakit, said Tuesday that it would file a supplemental new drug application to the FDA this year after the treatment reached main goals in a registration trial for patients with the non-advanced ...
Stock Information
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Get BPMC Alerts
News, Short Squeeze, Breakout and More Instantly...